Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure
Authors:
Open Access
- 22 August 2014
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 99 (11) , 1746-1752
Abstract
Second-line therapy for corticosteroid-refractory or -dependent acute graft-versus-host disease remains ill-defined, due to limited efficacy of drugs and evolving clinical trial endpoints. Six-month freedom from treatment failure has been proposed as a novel clinical trial endpoint and is defined by the absence of death, malignancy relapse/progression, or addition of a next line of systemic immunosuppressive therapy within 6 months of intervention and prior to diagnosis of chronic graft-versus-host disease. We analyzed the 6-month freedom from treatment failure endpoint in 128 patients enrolled from three centers who were treated with extracorporeal photopheresis as second-line therapy for acute graft-versus-host disease. The incidence of 6-month freedom from treatment failure was 77.3% with a 2-year survival rate of 56%. Corticosteroid dose or response status at onset of second-line therapy did not influence outcome. Higher grade of acute graft-versus-host disease (grade 2 versus grades 3–4) at onset of photopheresis predicted for poor outcome as measured by survival (hazard ratio 2.78, PP=0.001) and 6-month freedom from treatment failure (hazard ratio 3.05, Pversus-host disease using 6-month freedom from treatment failure as the primary endpoint.Keywords
This publication has 30 references indexed in Scilit:
- Risk factors for acute GVHD and survival after hematopoietic cell transplantationBlood, 2012
- Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomesBlood, 2009
- A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host diseaseBlood, 2008
- Study design and endpoints in graft-versus-host diseaseBest Practice & Research Clinical Haematology, 2008
- Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal CancerJournal of Clinical Oncology, 2007
- Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop☆Gynecologic Oncology, 2007
- Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line ChemotherapyJournal of Clinical Oncology, 2007
- Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulinBlood, 2006
- PREDNISONE THERAPY FOR ACUTE GRAFT-VERSUS-HOST DISEASETransplantation, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958